MiNK Therapeutics reports updated clinical results on agenT-797

MiNK Therapeutics (INKT) announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with advanced solid tumors refractory to all approved treatments presented at the Society for Immunotherapy of Cancer, SITC, Annual Meeting 2025. Durable and meaningful clinical benefit across tumor types: agenT-797, alone or in combination with anti-PD-1, demonstrated durable responses and disease stabilization in multiple checkpoint-refractory solid tumors, including germ cell testicular, thymoma, 2L gastric, cholangiocarcinoma, renal and adenoid cystic cancers, highlighting its potential to overcome resistance and extend benefit across tumor types. Complete and sustained remission beyond two years in metastatic germ-cell/testicular cancer, with full resolution of hepatic lesions and normalization of tumor markers. Immune Reactivation and Tumor-Immune Remodeling: Dual killing pathways: agenT-797 eliminates tumor cells through TCR-dependent and TCR-independent mechanisms. Restores immune function by activating dendritic cells, converting suppressive macrophages to pro-inflammatory M1 states, and reactivating exhausted T cells. Enhanced CD8 and NK-cell infiltration and coordinated cytokine activation reflect a potent but controlled immune response without systemic toxicity.